{"id":389252,"date":"2023-05-16T00:00:00","date_gmt":"2023-05-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0003-2023-biopharma-non-small-cell-lung-cancer-treatment-sequencing-us-2023\/"},"modified":"2026-03-31T10:33:48","modified_gmt":"2026-03-31T10:33:48","slug":"trsqon0003-2023-biopharma-non-small-cell-lung-cancer-treatment-sequencing-us-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0003-2023-biopharma-non-small-cell-lung-cancer-treatment-sequencing-us-2023\/","title":{"rendered":"Non-Small-Cell Lung Cancer | Treatment Sequencing | US | 2023"},"content":{"rendered":"<p><strong>Key benefits and uses<\/strong><\/p>\n<p><strong>Pinpoint<\/strong> current drug positioning and uptake in one snapshot to facilitate forecasting.<\/p>\n<p><strong>Drill down<\/strong> into physicians\u2019 treatment sequences and understand who to position against or how to defend share.<\/p>\n<p><strong>Identify<\/strong> untapped treatment scenarios and key competitors to aid trial design.<\/p>\n<p><strong>Evaluate<\/strong> unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.<\/p>\n<p><strong>Discover<\/strong> untapped populations to expand product share and drive strategic decisions.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<p>\u2022Where is my product positioned vs. competitors in the treatment journey?<\/p>\n<p>\u2022What are physicians\u2019 most frequent treatment sequences. Who is benefiting and how can I defend my asset\u2019s share and position?<\/p>\n<p>\u2022What are the market-relevant treatment scenarios according to oncology experts?<\/p>\n<p>\u2022Where are the untapped business opportunities that I can capitalize on?<\/p>\n<p>\u2022How can I optimize trial design and ensure a competitive edge for my pipeline asset?<\/p>\n<p><strong>GEOGRAPHY<\/strong><\/p>\n<p>United States.<\/p>\n<p><strong>PRIMARY MARKET RESEARCH<\/strong><\/p>\n<p>Survey of 100 U.S. medical oncologists.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts\u2019 assumptions.<\/p>\n","protected":false},"template":"","class_list":["post-389252","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389252\/revisions"}],"predecessor-version":[{"id":392383,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389252\/revisions\/392383"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}